Modest heterologous protection after Plasmodium falciparum sporozoite immunization: a double-blind randomized controlled clinical trial

Modest heterologous protection after Plasmodium falciparum sporozoite immunization: a double-blind randomized controlled clinical trial

Abstract Background A highly efficacious vaccine is needed for malaria control and eradication. Immunization with Plasmodium falciparum NF54 parasites under chemoprophylaxis (chemoprophylaxis and sporozoite (CPS)-immunization) induces the most efficient long-lasting protection against a homologous p...

Full description

Bibliographic Details
Main Authors: Jona Walk, Isaie J. Reuling, Marije C. Behet, Lisette Meerstein-Kessel, Wouter Graumans, Geert-Jan van Gemert, Rianne Siebelink-Stoter, Marga van de Vegte-Bolmer, Thorsten Janssen, Karina Teelen, Johannes H. W. de Wilt, Quirijn de Mast, André J. van der Ven, Ernest Diez Benavente, Susana Campino, Taane G. Clark, Martijn A. Huynen, Cornelus C. Hermsen, Else M. Bijker, Anja Scholzen, Robert W. Sauerwein
Format: Article
Language:English
Published: BMC 2017-09-01
Series:BMC Medicine
Subjects:
Plasmodium falciparum
Malaria
Vaccine
Sporozoite
Controlled human malaria infection
Heterologous protection
Online Access:http://link.springer.com/article/10.1186/s12916-017-0923-4

Internet

http://link.springer.com/article/10.1186/s12916-017-0923-4

Similar Items